Ranger Investment Management L.P. Purchases New Stake in ANI Pharmaceuticals, Inc. $ANIP

Ranger Investment Management L.P. purchased a new stake in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 343,150 shares of the specialty pharmaceutical company’s stock, valued at approximately $28,406,000. ANI Pharmaceuticals accounts for approximately 1.8% of Ranger Investment Management L.P.’s holdings, making the stock its 17th largest holding. Ranger Investment Management L.P. owned about 1.51% of ANI Pharmaceuticals at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in ANIP. Sanctuary Advisors LLC purchased a new position in shares of ANI Pharmaceuticals in the second quarter valued at about $1,139,000. Globeflex Capital L P purchased a new stake in shares of ANI Pharmaceuticals during the second quarter worth about $8,987,000. Kendall Capital Management purchased a new stake in shares of ANI Pharmaceuticals during the second quarter worth about $612,000. Elevation Point Wealth Partners LLC bought a new stake in shares of ANI Pharmaceuticals in the second quarter worth about $300,000. Finally, Quantbot Technologies LP bought a new stake in shares of ANI Pharmaceuticals in the second quarter worth about $505,000. Institutional investors own 76.05% of the company’s stock.

ANI Pharmaceuticals Price Performance

ANIP opened at $75.35 on Monday. The stock has a fifty day simple moving average of $80.36 and a two-hundred day simple moving average of $78.88. The company has a current ratio of 2.91, a quick ratio of 2.41 and a debt-to-equity ratio of 0.99. The company has a market cap of $1.73 billion, a price-to-earnings ratio of 16.24 and a beta of 0.44. ANI Pharmaceuticals, Inc. has a 12-month low of $70.15 and a 12-month high of $99.50.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings data on Friday, August 7th. The specialty pharmaceutical company reported $2.21 EPS for the quarter, beating the consensus estimate of $2.04 by $0.17. ANI Pharmaceuticals had a return on equity of 27.37% and a net margin of 11.07%.The business had revenue of $266.04 million during the quarter, compared to analyst estimates of $260.13 million. During the same quarter last year, the firm posted $1.80 earnings per share. The company’s revenue for the quarter was up 25.8% on a year-over-year basis. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. Research analysts predict that ANI Pharmaceuticals, Inc. will post 7.83 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on ANIP shares. Canaccord Genuity Group lowered their price target on ANI Pharmaceuticals from $91.00 to $90.00 and set a “hold” rating for the company in a research report on Monday, August 10th. Zacks Research lowered ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Thursday, May 14th. Weiss Ratings lowered ANI Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday, August 11th. Guggenheim reduced their target price on ANI Pharmaceuticals from $124.00 to $119.00 and set a “buy” rating on the stock in a research note on Monday, August 10th. Finally, Wall Street Zen downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Four equities research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, ANI Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $105.83.

Insider Buying and Selling at ANI Pharmaceuticals

In related news, VP Meredith Cook sold 500 shares of ANI Pharmaceuticals stock in a transaction dated Thursday, August 13th. The shares were sold at an average price of $75.48, for a total transaction of $37,740.00. Following the completion of the transaction, the vice president directly owned 74,424 shares of the company’s stock, valued at $5,617,523.52. This trade represents a 0.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Ori Gutwerg sold 3,162 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $77.00, for a total transaction of $243,474.00. Following the sale, the senior vice president directly owned 75,534 shares in the company, valued at $5,816,118. The trade was a 4.02% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 18,987 shares of company stock valued at $1,546,405 in the last quarter. 8.10% of the stock is owned by insiders.

ANI Pharmaceuticals Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.